Neoplasms, Unknown Primary clinical trials
The registry lists 101 studies for Neoplasms, Unknown Primary across more than 10 countries. 19 are recruiting or about to start. 53 of them are mainly about Neoplasms, Unknown Primary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Neoplasms, Unknown Primary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (6) · SCRI Development Innovations, LLC (5) · University Health Network, Toronto (4) · Rigshospitalet, Denmark (4) · The Christie NHS Foundation Trust (3) · National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (3) · Mayo Clinic (2)
What is being tested here
Drugs under test in Neoplasms, Unknown Primary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| FAPI-46 | 1 | 0 | 2 |
| Atezolizumab | 1 | 0 | 2 |
| Rulonilimab | 1 | 1 | 1 |
| Pegsitacianine | 1 | 0 | 1 |
| Paclitaxel | 0 | 2 | 10 |
| Carboplatin | 0 | 2 | 9 |
| Gemcitabine | 0 | 1 | 8 |
| Capecitabine | 0 | 0 | 7 |
| Irinotecan | 0 | 1 | 6 |
| Oxaliplatin | 0 | 0 | 4 |
Drug classes tested here Immune checkpoint inhibitors 2 open · Antimetabolites 18 · Antimitotic agents 14 · Tyrosine kinase inhibitors (TKIs) 4 · Alkylating agents 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8
- Dec 2026Enabling Genomic Testing in Cancer of Unknown Primary · The Christie NHS Foundation Trust
- Dec 2026PaCIFiC-CUP Classifies Cancer of Unknown Primary · Sun Yat-sen University
- Jul 2027Integrated Molecular Profiling in Advanced Cancers Trial · University Health Network, Toronto
- Aug 2027Ontario-wide Cancer TArgeted Nucleic Acid Evaluation · University Health Network, Toronto
- Aug 2027Solving Riddles Through Sequencing · Munich Leukemia Laboratory
- Sep 2027Living Without Answers - ILLUMINATE CUP · The Clatterbridge Cancer Centre NHS Foundation Trust
- Oct 2027Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity · British Columbia Cancer Agency
- Oct 2027Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord · M.D. Anderson Cancer Center
Who these studies take
Of the 15 Neoplasms, Unknown Primary studies recruiting now, 10 (67%) set no upper age limit and 1 (7%) stop at 75 or younger. 1 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 14 (93%) | 14 (93%) |
| 30 | 15 (100%) | 15 (100%) |
| 40 | 15 (100%) | 15 (100%) |
| 50 | 15 (100%) | 15 (100%) |
| 65 | 15 (100%) | 15 (100%) |
| 75 | 15 (100%) | 15 (100%) |
| 85 | 13 (87%) | 13 (87%) |
Across all 101 studies, recruiting or not: 8% stop at 75 or younger and 3% at 65; 8% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 101. Browse all 101 → or search them.
- Smartphone-Based Self-Registration of Health Data in Patients With Severe Unspecific Symptoms or Cancer of Unknown PrimaryNot yet recruitingNCT07898280Not applicable1 country
- Solving Riddles Through SequencingRecruitingNCT050464441 country
- Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck CancerRecruitingNCT030101501 country
- Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 21 country
- Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)RecruitingNCT075241141 country
- A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)RecruitingNCT07761429Phase 2/31 country
- Living Without Answers - ILLUMINATE CUPNot yet recruitingNCT07712965
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Ontario-wide Cancer TArgeted Nucleic Acid EvaluationRecruitingNCT029069431 country
- TCF-001 TRACK (Target Rare Cancer Knowledge) StudyRecruitingNCT04504604Not applicable1 country
- PaCIFiC-CUP Classifies Cancer of Unknown PrimaryRecruitingNCT061409921 country
- A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)RecruitingNCT05576974Phase 21 country
- Cancer Genetic Testing in Ethnic PopulationsRecruitingNCT04475640Not applicable1 country
- Enabling Genomic Testing in Cancer of Unknown PrimaryRecruitingNCT066954941 country
- 18F-FAPI PET in Cancers of Unknown Primary SiteNot yet recruitingNCT073729631 country
- The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)Not yet recruitingNCT07366008Not applicable1 country
- Genomic Investigation of Unusual RespondersRecruitingNCT037405031 country
- Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and NeckRecruitingNCT06100081Not applicable1 country
- FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown PrimaryRecruitingNCT05263700Not applicable1 country
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersActive, not recruitingNCT04459273Phase 11 country
- HARE-40: HPV Anti-CD40 RNA vaccinECompletedNCT03418480Phase 1/21 country
- Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 21 country
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 11 country
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 21 country
- Integrated Molecular Profiling in Advanced Cancers TrialActive, not recruitingNCT015054001 country
- Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)CompletedNCT03391973Phase 21 country
- A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicable1 country
- Trial of Pembrolizumab in Cancer of Unknown PrimaryCompletedNCT03752333Phase 21 country
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT054614301 country
- Sintilimab in Cancer of Unknown PrimaryCompletedNCT05024968Phase 21 country
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 233 countries
- Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
- Genomic Testing and Resulting Medical DecisionsCompletedNCT033014931 country
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 21 country
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
- Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsActive, not recruitingNCT04584008Not applicable1 country
- Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid BiomarkersCompletedNCT047501091 country
- Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown PrimaryCompletedNCT05841966Not applicable1 country
- A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)CompletedNCT02607202Phase 21 country
- Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit StudyCompletedNCT04456140Phase 11 country
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid TumorsWithdrawnNCT00499291Not applicable
- Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineCompletedNCT01845337Phase 21 country
- Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSASCompletedNCT04189107Phase 31 country
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 21 country
- APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 11 country
- Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown PrimaryCompletedNCT03278600Phase 31 country
- Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in ChinaStatus unknownNCT049521031 country
- Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary OriginTerminatedNCT00003526Phase 21 country
- The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT038969581 country